Immunocore Holdings plc - American Depositary Shares (IMCR)
IMCR moved a median of +0.07% 30 minutes after news, and +0.04% by the close. How IMCR actually reacts to news — the realized, point-in-time move the market made, measured across 296 labeled events over the last three years with zero look-ahead.
IMCR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 292 |
| 30-min | +0.07% | 53% | 296 |
| 60-min | -0.13% | 46% | 296 |
| to close | +0.04% | 51% | 296 |
| Middle 50% of IMCR reactions | -1.12% to +0.80% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 296 |
Half of all Immunocore Holdings plc - American Depositary Shares news events land between -1.12% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IMCR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.02% | 50% | -1.76% |
| Analyst downgrades | 21 | -0.20% | 48% | +0.59% |
| Coverage initiations | 26 | -0.87% | 39% | -0.84% |
| Rating reiterations | 86 | -0.02% | 49% | +0.09% |
| Price-target raises | 10 | +0.30% | 60% | -0.37% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how IMCR ranks against every other measured name →
That’s how IMCR usually reacts — get an email when it moves on news →Email me when IMCR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMCR's baseline. Nothing else.
Recent IMCR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes | Press release | GlobeNewswire | +0.91% | +2.61% | |
| Form 8-K Immunocore Holdings plc For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | -1.34% | |
| Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma | Press release | GlobeNewswire | -0.70% | -1.34% | |
| Immunocore to present at upcoming investor conferences | Press release | GlobeNewswire | -1.78% | +0.99% | |
| The Galien Foundation Announces 2026 International Prix Galien Award Nominees | Press release | PR Newswire | +0.17% | +2.65% | |
| Form 10-Q Immunocore Holdings plc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.49% | +5.05% | |
| Form 8-K Immunocore Holdings plc For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | +5.05% | |
| Immunocore reports second quarter financial results and provides a business update | Press release | GlobeNewswire | +0.49% | +5.05% | |
| Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 | Press release | GlobeNewswire | +0.51% | +1.83% | |
| Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma | Press release | GlobeNewswire | -0.48% | +0.83% | |
| Form 8-K Immunocore Holdings plc For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | +1.86% | |
| Form S-8 Immunocore Holdings plc | SEC filing · Form S-8 | SEC EDGAR | -0.07% | -3.40% | |
| Form 10-Q Immunocore Holdings plc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.07% | +3.02% | |
| Form 8-K Immunocore Holdings plc For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +3.02% | |
| Immunocore reports first quarter financial results and provides a business update | Press release | GlobeNewswire | +1.07% | +3.02% | |
| KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma | Press release | GlobeNewswire | -0.79% | -0.16% | |
| Form ARS Immunocore Holdings plc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.47% | -1.26% | |
| Form DEF 14A Immunocore Holdings plc For: May 27 | SEC filing · Form DEF | SEC EDGAR | -0.47% | -1.26% | |
| Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform | Press release | Business Wire | +0.98% | -0.22% | |
| Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.64% | +2.47% | |
| Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer | Press release | GlobeNewswire | +0.93% | +0.56% | |
| Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting | Press release | GlobeNewswire | -0.60% | -2.44% | |
| Immunocore to present at upcoming investor conferences | Press release | GlobeNewswire | -1.06% | +0.75% | |
| Form 10-K Immunocore Holdings plc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.00% | -1.05% | |
| Form 8-K Immunocore Holdings plc For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +3.00% | -1.05% | |
| Immunocore reports fourth quarter and full year 2025 financial results and provides a business update | Press release | GlobeNewswire | +3.00% | -1.05% | |
| Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 | Press release | GlobeNewswire | +0.95% | +0.03% | |
| VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors | Press release | Business Wire | +0.19% | -1.56% | |
| Levicept Announces the Appointment of James Sandy as Chief Development Officer | Press release | GlobeNewswire | -0.28% | -2.14% | |
| Form 8-K Immunocore Holdings plc For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | +0.40% | |
| Immunocore announces R&D leadership evolution | Press release | GlobeNewswire | +0.28% | +0.40% | |
| Form 8-K Immunocore Holdings plc For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -1.58% | |
| Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.21% | -1.58% | |
| Form 8-K Immunocore Holdings plc For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -1.25% | |
| The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for "Best Bridge-Builder Institution," "Best Biomedical Product," "Best Medical Technology/AI Advances in Human Health," "Best Product for Rare/Orphan Diseases," and "Best Public Sec | Press release | PR Newswire | +0.00% | +3.99% | |
| Immunocore to present at upcoming investor conferences | Press release | GlobeNewswire | +1.59% | +3.12% | |
| Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting | Press release | GlobeNewswire | +0.68% | +5.78% | |
| Form 10-Q Immunocore Holdings plc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.66% | |
| Form 8-K Immunocore Holdings plc For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.66% | |
| Immunocore reports third quarter financial results and provides a business update | Press release | GlobeNewswire | +0.00% | +1.66% | |
| Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer | Press release | GlobeNewswire | +0.04% | -1.54% | |
| Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer | Press release | PR Newswire | -0.05% | -1.15% | |
| Immunocore to present at upcoming investor conferences | Press release | GlobeNewswire | -0.42% | -0.79% | |
| TLR7/8 Agonists Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight | Press release | PR Newswire | +0.60% | -0.22% | |
| Uveal Melanoma Market Analysis Across the 7MM: Key Insights and Outlook Through 2034 | DelveInsight | Press release | PR Newswire | +0.00% | +0.12% | |
| Form 10-Q Immunocore Holdings plc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.68% | |
| Form 8-K Immunocore Holdings plc For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.68% | |
| Immunocore reports second quarter financial results and provides a business update | Press release | GlobeNewswire | +0.00% | -0.68% | |
| Immunocore to report second quarter 2025 financial results and host call on August 7, 2025 | Press release | GlobeNewswire | +0.00% | -1.62% | |
| Claudin 18.2-Directed Oncology Therapeutics--A Fast-Growing Market with Blockbuster Potential | DelveInsight | Press release | PR Newswire | +0.85% | -2.03% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMCR section they belong to.
Where else IMCR is measured.
IMCR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Immunocore Holdings plc - American Depositary Shares's median reaction calculated?
Every labeled IMCR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 296 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of IMCR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMCR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.